By Connor Hart
Shares of Trinity Biotech climbed after the company released what it called compelling results from a study of its next-generation continuous glucose monitoring system, a device used for diabetes management that measures blood sugar levels in real time.
The stock was up 41%, to $1.07, in midday trading Tuesday. Shares are down 52% in the past 52 weeks.
The Dublin-based biotechnology company on Tuesday said the new system demonstrated better signal quality, accuracy and consistency than did previous generations in a recent trial involving 30 diabetic participants.
The new system also features a reusable applicator and a rechargeable wearable transmitter, eliminating costly disposable components and allowing the product to be made at a significantly lower cost, Trinity said.
Moving forward, the company said it expects to complete further clinical trials on the device. It remains on track to file for regulatory approval in the EU in 2025, and in the U.S. in 2026.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 28, 2025 11:59 ET (16:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。